Philips Launches 7 Clinical Studies to Treat Tumors and Aneurysms with AI
Royal Philips has announced the initiation of seven clinical studies coordinated by the SHERPA consortium to validate AI and robotics-based assistive technologies in the treatment of cerebral aneurysms and liver tumors. The project aims to alleviate the workload of interventional radiologists amidst staff shortages.
Innovative AI Technologies to Revolutionize Treatment
The SHERPA consortium, led by Philips, will validate AI technologies covering imaging, data visualization, intervention planning, procedural guidance, clinical decision support, and patient journey orchestration. These technologies are designed to automate repetitive and time-consuming tasks, support decision-making, and accelerate practitioner learning. In the project's first year, the consortium developed algorithms to identify cerebral aneurysms requiring treatment, optimize patient selection and therapeutic planning for liver tumor ablation, and robotic technologies to enhance procedural accuracy. These elements have been integrated into end-to-end orchestrated workflows for both types of procedures.
A Four-Year Project Supported by European Partners
The four-year project is co-funded by industrial partners and the European Union's Innovative Health Initiative. It includes sixteen partners from seven European countries. Over the next three years, consortium partners will conduct a series of clinical studies to refine assistive technologies and assess their benefits in terms of patient experience, workload optimization, stakeholder satisfaction, and performance. The five studies dedicated to cerebral aneurysms will focus on AI-assisted detection, risk prediction, and precise treatment planning. The studies on liver and lung tumors will leverage advanced imaging technologies and robot-assisted biopsy.
